866-997-4948(US-Canada Toll Free)

Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023

Published By :

DelveInsight

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 88 Pages

Acne vulgaris is a common chronic skin disease/Disorder of pilosebaceous follicles. The disease is characterized by blockage and/or inflammation of hair follicles and their accompanying sebaceous gland. Acne develops in regions of high sebaceous gland. The disease is seen to occur mostly in adolescence. At puberty androgens due to the increase in sebum production from enlarged sebaceous glands, the glands become blocked. Propionibacterium acnes further colonise and lead to lesion production although its exact role is unclear.
DelveInsights Acne Vulgaris (AV) - Market Insights, Epidemiology and Market Forecast-2023 Report provides an overview of the disease and market size of the Acne Vulgaris for the global, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the Acne Vulgaris Diagnosed Cases from 2013-2023. According to DelveInsight, the Diagnosed cases in 7 major markets for Acne Vulgaris (AV) were 113,959,366 cases in 2013 and are expected to be 136,929,289 cases in 2023.
As per DelveInsights estimation, the global market size of Acne Vulgaris (AV) was USD 5,360.1 Millions in 2013 and is expected to reach USD 14,226.3 Million by the end of 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
- It also provides Market size of Acne Vulgaris (AV) for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
Report Introduction
Acne Vulgaris Market Overview at a Glance
Total Market Size of Acne Vulgaris for 7 MM in 2010-2023
Total Market Share Distribution of Acne Vulgaris for 7 MM in 2015
Total Market Share Distribution of Acne Vulgaris for 7 MM in 2023
Acne Vulgaris
Overview
Signs and symptoms
Types of Acne
Pathophysiology
Diagnosis
Epidemiology and Patient Population
United States
Diagnosed Cases of Acne Vulgaris in United States
Germany
Diagnosed Cases of Acne Vulgaris in Germany
France
Diagnosed Cases of Acne Vulgaris in France
United Kingdom
Diagnosed Cases of Acne Vulgaris in United Kingdom
Spain
Diagnosed Cases of Acne Vulgaris in Spain
Italy
Diagnosed Cases of Acne Vulgaris in Italy
Japan
Diagnosed Cases of Acne Vulgaris in Japan
Treatment Algorithm
Marketed Drugs
Top Marketed Drugs for Acne Vulgaris
Acanya: Valeant Pharmaceuticals
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Acanya
Product Profile
Tazorac: Allergan
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Tazorac
Product Profile
Veltin: Almirall, S.A.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Duac: Glaxosmithkline
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Epiduo and Epiduo Forte: Galderma S.A.
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Epiduo
Product Profile
Emerging Therapies
Major Pipeline drugs
Sarecycline: Paratek Pharmaceuticals
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Aczone reform: Allergan
Advantages & Disadvantages
Product Profile
SB204: Novan, Inc.
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Global Acne Vulgaris: Country-Wise Market Analysis
Overview on Total Acne Vulgaris Market (2015)
Overview on Total Acne Vulgaris Market (2023)
United States Market Size
Europe Market Size
United Kingdom Market Size
Germany Market Size
France Market Size
Italy Market Size
Spain Market Size
Japan Market Size
Market Drivers
Market Restraints
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Table

Table 1: Diagnosed Cases Acne Vulgaris in United States (2013-2023)
Table 2: Diagnosed Cases Acne Vulgaris in Germany (2013-2023)
Table 3: Diagnosed Cases Acne Vulgaris in France (2013-2023)
Table 4: Diagnosed Cases Acne Vulgaris in United Kingdom (2013-2023)
Table 5: Diagnosed Cases Acne Vulgaris in Spain (2013-2023)
Table 6: Diagnosed Cases Acne Vulgaris in Italy (2013-2023)
Table 7: Diagnosed Cases Acne Vulgaris in Japan (2013-2023)
Table 8: List of Marketed Drugs for Acne Vulgaris
Table 9: List of Pipeline Phase III Drugs for Acne Vulgaris
Table 10: Sarecycline, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: SB204, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: United States Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 15: United Kingdom Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 16: Germany Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 17: France Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 18: Italy Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 19: Spain Market Size of Acne Vulgaris in USD, Million (2013-2023)
Table 20: Japan Market Size of Acne Vulgaris in USD, Million (2013-2023)

List of Chart

Figure 1: Cellular mechanisms hypothesized to govern the pathogenesis of Acne Vulgaris
Figure 2: Diagnosed Cases of Acne Vulgaris in United States (2013-2023)
Figure 3: Diagnosed Cases of Acne Vulgaris in Germany (2013-2023)
Figure 4: Diagnosed Cases of Acne Vulgaris in France (2013-2023)
Figure 5: Diagnosed Cases of Acne Vulgaris in United Kingdom (2013-2023)
Figure 6: Diagnosed Cases of Acne Vulgaris in Spain (2013-2023)
Figure 7: Diagnosed Cases of Acne Vulgaris in Italy (2013-2023)
Figure 8: Diagnosed Cases of Acne Vulgaris in Japan (2013-2023)
Figure 9: Sarecycline, Clinical Trials by Zone (%), 2017
Figure 10: Sarecycline, Clinical Trials by Trial status (%), 2017
Figure 11: SB204, Clinical Trials by Zone (%), 2017
Figure 12: SB204, Clinical Trials by Trial status (%), 2017
Figure 13: Total Market Size of Acne Vulgaris in USD, Million (2015)
Figure 14: Total Market Size of Acne Vulgaris in USD, Million (2023)
Figure 15: United States Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 16: United Kingdom Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 17: Germany Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 18: France Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 19: Italy Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 20: Spain Market Size of Acne Vulgaris in USD, Million (2013-2023)
Figure 21: Japan Market Size of Acne Vulgaris in USD, Million (2013-2023)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *